Cargando…

Supportive Care Costs Associated with Second-Line Chemotherapy in Chinese Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Cohort Study

PURPOSE: To compare supportive care costs associated with second-line chemotherapy for advanced non-squamous non-small cell lung cancer (advNS-NSCLC) in Chinese patients. METHODS: This retrospective cohort study included patients receiving pemetrexed or docetaxel-based second-line chemotherapy for a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Xiaoling, Wang, Yuqin, Wang, Yan, Chen, Jianhua, Wu, Shengqi, Hu, Chenping, Yang, Yicheng, Rajan, Narayan, Papadimitropoulos, Manny, Chen, Yi, Peng, Tao, Chen, Wendong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2015
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4883204/ https://www.ncbi.nlm.nih.gov/pubmed/27747618 http://dx.doi.org/10.1007/s40801-015-0017-6

Ejemplares similares

Clinical effectiveness and clinical toxicity associated with platinum-based doublets in the first-line setting for advanced non-squamous non-small cell lung cancer in Chinese patients: a retrospective cohort study
por: Wang, Yan, et al.
Publicado: (2014)

Real-world hospital costs for nonchemotherapy drugs and nondrug care associated with platinum-based doublets in the first-line setting for advanced nonsquamous non-small-cell lung cancer in Chinese patients: a retrospective cohort study
por: Chen, Jianhua, et al.
Publicado: (2016)

Clinical response and hospital costs associated with the empirical use of vancomycin and linezolid for hospital-acquired pneumonia in a Chinese tertiary care hospital: a retrospective cohort study
por: Song, Yuanlin, et al.
Publicado: (2014)

Cost-effectiveness of camrelizumab plus chemotherapy vs. chemotherapy in the first-line treatment of non-squamous NSCLC: Evidence from China
por: Dai, Hongbin, et al.
Publicado: (2023)

Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer
por: Liang, Xueyan, et al.
Publicado: (2023)

Cost-Effectiveness of Nivolumab Immunotherapy vs. Paclitaxel or Docetaxel Chemotherapy as Second-Line Therapy in Advanced Esophageal Squamous Cell Carcinoma in China
por: Lin, Ying-tao, et al.
Publicado: (2022)

Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer
por: Gao, Guanghui, et al.
Publicado: (2022)

The Opportunity Cost of Capital: Development of New Pharmaceuticals
por: Chit, Ayman, et al.
Publicado: (2015)

Bevacizumab/PD-1 inhibitor plus chemotherapy as first-line treatment of advanced non-squamous non-small-cell lung cancer
por: Wang, Jing, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Camrelizumab Immunotherapy versus Docetaxel or Irinotecan Chemotherapy as Second-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma
por: Lin, Ying-Tao, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma
por: Cai, Hongfu, et al.
Publicado: (2021)

A Markov Model Approach Assessing the Cost of Illness of Generalized Anxiety Disorder in Canada
por: Bereza, Basil G., et al.
Publicado: (2012)

Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population
por: Asukai, Yumi, et al.
Publicado: (2010)

Oligorecurrence Non–small Cell Lung Cancer After Failure of First-Line Chemotherapy: Computed Tomography–Guided (125)I Seed Implantation vs. Second-Line Chemotherapy
por: Wang, Hao, et al.
Publicado: (2020)

Cost Analyses in the US and Japan: A Cross-Country Comparative Analysis Applied to the PRONOUNCE Trial in Non-Squamous Non-Small Cell Lung Cancer
por: Hess, Lisa M., et al.
Publicado: (2015)

PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancer
por: Yu, Hui, et al.
Publicado: (2021)

Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non–small cell lung cancer in China
por: Liu, Huiqin, et al.
Publicado: (2022)

Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma
por: Liu, Lulu, et al.
Publicado: (2023)

Correction: Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non–small cell lung cancer in China
por: Liu, Huiqin, et al.
Publicado: (2023)

Cost-effectiveness analysis of camrelizumab in the second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China
por: Yang, Fan, et al.
Publicado: (2021)

Cost-effectiveness of pembrolizumab versus docetaxel as second-line treatment of non-small cell lung cancer in China
por: Shi, Yafei, et al.
Publicado: (2021)

The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer
por: Lu, Tingting, et al.
Publicado: (2023)

Outcomes of Second-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer in One Institution
por: Lee, Seok Jeong, et al.
Publicado: (2014)

Efficacy of second-line chemotherapy after immunotherapy in advanced non-small cell lung cancer
por: Hirata, Tsuyoshi, et al.
Publicado: (2023)

Sintilimab plus autologous NK cells as second-line treatment for advanced non-small-cell lung cancer previous treated with platinum-containing chemotherapy
por: Jia, Lin, et al.
Publicado: (2022)

Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study
por: Shen, Lin, et al.
Publicado: (2022)

Cost-effectiveness of bortezomib for multiple myeloma: a systematic review
por: Chen, Wendong, et al.
Publicado: (2016)

Irinotecan plus fluorouracil‐based regimen as second or third‐line chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma
por: Wang, Xi, et al.
Publicado: (2015)

Efficacy and safety of immunotherapy combined with single-agent chemotherapy as second- or later-line therapy for metastatic non-small cell lung cancer
por: Chen, Dongna, et al.
Publicado: (2023)

A prognostic model for platinum‐doublet as second‐line chemotherapy in advanced non‐small‐cell lung cancer patients
por: Mo, Hongnan, et al.
Publicado: (2016)

A retrospective analysis of safety and efficacy of weekly nab-paclitaxel as second-line chemotherapy in elderly patients with advanced squamous non-small-cell lung carcinoma
por: Jin, Feng, et al.
Publicado: (2016)

Real-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naïve patients
por: Chen, You-Yi, et al.
Publicado: (2021)

Cost-Effectiveness of Second-Line Chemotherapy/Biologics among Elderly Metastatic Colon Cancer Patients
por: Zheng, Zhiyuan, et al.
Publicado: (2014)

Cost-effectiveness analysis of pembrolizumab vs. chemotherapy as second-line treatment for advanced esophageal carcinoma in the United States
por: Hu, Jia, et al.
Publicado: (2022)

Economic evaluation of tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China
por: Shi, Fenghao, et al.
Publicado: (2022)

OPTIMAL and ENSURE trials-based combined cost-effectiveness analysis of erlotinib versus chemotherapy for the first-line treatment of Asian patients with non-squamous non-small-cell lung cancer
por: Wen, Feng, et al.
Publicado: (2018)

Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy
por: Grossi, F, et al.
Publicado: (2017)

Cost‐effectiveness of first‐line versus second‐line use of domestic anti‐PD‐1 antibody sintilimab in Chinese patients with advanced or metastatic squamous non‐small cell lung cancer
por: Cheng, Rihua, et al.
Publicado: (2022)

Cost comparison of second-line treatment options for late stage non-small-cell lung cancer: cost analysis for Italy
por: Schwander, Bjoern, et al.
Publicado: (2012)

Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer in China
por: Zhang, Xin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jlerj5h9s484op6ks5g8o9c0rl